Cited by 573Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular DiseasesDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank

Open access

Patel, Aniruddh P., Wang, Minxian, Pirruccello, James P., Ellinor, Patrick T., Ng, Kenney, Kathiresan, Sekar, Khera, Amit V.·2021·Arteriosclerosis, Thrombosis, and Vascular Biology

DOI 10.1161/atvbaha.120.315291PMC PMC7769893

Open this paper in CoChat — free account Open PDF

Abstract

Objective: Lp(a) (lipoprotein[a]) concentrations are associated with atherosclerotic cardiovascular disease (ASCVD), and new therapies that enable potent and specific reduction are in development. In the largest study conducted to date, we address 3 areas of uncertainty: (1) the magnitude and shape of ASCVD risk conferred across the distribution of lipoprotein(a) concentrations; (2) variation of risk across racial and clinical subgroups; (3) clinical importance of a high lipoprotein(a) threshold to guide therapy. Approach and Results: Relationship of lipoprotein(a) to incident ASCVD was studied in 460 506 middle-aged UK Biobank participants. Over a median follow-up of 11.2 years, incident ASCVD occurred in 22 401 (4.9%) participants. Median lipoprotein(a) concentration was 19.6 nmol/L (25th–75th percentile 7.6–74.8). The relationship between lipoprotein(a) and ASCVD appeared linear across the distribution, with a hazard ratio of 1.11 (95% CI, 1.10–1.12) per 50 nmol/L increment. Substantial differences in concentrations were noted according to race—median values for white, South Asian, black, and Chinese individuals were 19, 31, 75, and 16 nmol/L, respectively. However, risk per 50 nmol/L appeared similar—hazard ratios of 1.11, 1.10, and 1.07 for white, South Asian, and black individuals, respectively. A high lipoprotein(a) concentration defined as ≥150 nmol/L was present in 12.2% of those without and 20.3% of those with preexisting ASCVD and associated with hazard ratios of 1.50 (95% CI, 1.44–1.56) and 1.16 (95% CI, 1.05–1.27), respectively. Conclusions: Lipoprotein(a) concentrations predict incident ASCVD among middle-aged adults within primary and secondary prevention contexts, with a linear risk gradient across the distribution. Concentrations are variable across racial subgroups, but the associated risk appears similar.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/atvbaha.120.315291

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437741.48606.98 · Cited by 3,697
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations
Khera, A. V., Chaffin, M., Aragam, K. G., Haas, M. E., Roselli, C., Choi, S. H., Natarajan, P., Lander, E. S., Lubitz, S. A., Ellinor, P. T., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0183-z · Cited by 2,953
Self-citation
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
A NEW SERUM TYPE SYSTEM IN MAN—THE Lp SYSTEM
Berg, K. (1963) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/j.1699-0463.1963.tb01808.x · Cited by 1,383

Flagged first, then by citations

Show all 50 references

Sorted by citations

Items 201–300 of 573

Elevated lipoprotein(a) as a predictor for coronary events in older men
Bartoli‐Leonard, F., Turner, M. E., Zimmer, J., Chapurlat, R. D., Pham, T., Aikawa, M., Pradhan, A. D., Szulc, P., & Aikawa, E. R. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100242 · Cited by 10
Heightened risks of cardiovascular disease in South Asian populations: causes and consequences
Stefil, M., Bell, J. W., Calvert, P. A. R., & Lip, G. Y. H. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2187780 · Cited by 10
Lipoprotein(a): A Residual Cardiovascular Risk Factor in Statin-Treated Stroke Survivors
Chemello, K., Gallo, A., Guédon, A. F., Techer, R., Croyal, M., Swietek, M. J., Meilhac, O., Amarenco, P., & Lambert, G. C. (2023) · JACC Advances · doi:10.1016/j.jacadv.2023.100557 · Cited by 11
Association between lipoprotein(a) and insulin resistance in Chinese adults: results from the China health and nutrition survey
Wang, H., & Fan, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1234140 · Cited by 10
Synergetic impact of lipoprotein(a) and fibrinogen on stroke in coronary artery disease patients
Yang, C. X., Zhu, C., Sui, Y., Guo, Y., Wu, N., Dong, Q., Xu, R., Qian, J., & Li, J. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14179 · Cited by 10
The Role of mtDNA Mutations in Atherosclerosis: The Influence of Mitochondrial Dysfunction on Macrophage Polarization
Fedotova, E. I., Berezhnov, A. V., Popov, D. Y., Shitikova, E. Y., & Vinokurov, A. Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031019 · Cited by 10
Elevated lipoprotein(a) levels linked to new-onset atrial fibrillation: insights from a retrospective cohort study
Awad, K., Kamel, M., Mahmoud, A., Farina, J., Badr, A., Pereyra, M., Scalia, I. G., Abbas, M. T., Ali, N. B., Alsidawi, S., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf063 · Cited by 10
Elevated lipoprotein(a) levels: A crucial determinant of cardiovascular disease risk and target for emerging therapies
Afzal, Z., Cao, H., Chaudhary, M. A., Chigurupati, H. D., Neppala, S., Alruwaili, W., Awad, M. A., Sandesara, D., Siddique, M., Farman, A., et al. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102586 · Cited by 9
Lipoprotein(a) in children and adolescents with genetically confirmed familial hypercholesterolemia followed up at a specialized lipid clinic
Johansen, A. K., Bogsrud, M. P., Thoresen, M., Christensen, J. J., Narverud, I., Langslet, G., Svilaas, T., Retterstøl, K., & Holven, K. B. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.06.002 · Cited by 9
Consensus on lipoprotein(a) of the Spanish Society of Arteriosclerosis. Literature review and recommendations for clinical practice
Delgado‐Lista, J., Mostaza, J. M., Arrobas-Velilla, T., Blanco‐Vaca, F., Masana, L., Pedro‐Botet, J., Pérez‐Martínez, P., Civeira, F., Cuende, J. I., Gómez-Barrado, J. J., et al. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2024.07.008 · Cited by 9
Statins—Their Effect on Lipoprotein(a) Levels
Granat, M. M. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm26162 · Cited by 9
Association of lipoprotein(a) and diabetes in primary prevention of coronary heart disease: The Multi-Ethnic Study of Atherosclerosis (MESA)
Rikhi, R. R., Haidar, A., Bhatia, H. S., Beam, K., McParland, J., Kazibwe, R., Chevli, P. A., Schaich, C. L., Sanghavi, M., & Shapiro, M. D. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119179 · Cited by 9
Lipoprotein(a) and Cardiovascular Risk in Asian Populations: A Comprehensive Review
Kim, J. A., & Kim, N. H. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.2.174 · Cited by 11
Rationale for the routine screening of Lipoprotein(a) in cardiovascular risk assessment
Iatan, I., Koschinsky, M. L., Trenaman, L., Zhang, W., Thanassoulis, G., Brunham, L. R., Mancini, G. B. J., & Francis, G. A. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf342 · Cited by 11
Lipoprotein (a) in primary cardiovascular disease prevention is actionable today
Parcha, V., & Bittner, V. (2025) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2025.100581 · Cited by 9
Primary Prevention Aspirin, Lipoprotein(a), and Cardiorenal Outcomes in Chronic Kidney Disease
Razavi, A. C., Chen, J., Yang, W. P., Sha, D., Dzaye, O., Bhatia, H. S., Tsimikas, S., Lash, J. P., Kansal, M. M., Rincon-Choles, H., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.102068 · Cited by 9
Lipoprotein(a) and Venous Thromboembolism: Association, Causality, and Medications
Pfeferman, M. B., Rashedi, S., Lip, G. Y. H., Weber, C., O’Donoghue, M. L., Nissen, S. E., Nicholls, S. J., Natarajan, P., Plutzky, J., Libby, P., et al. (2025) · Thrombosis and Haemostasis · doi:10.1055/a-2674-5114 · Cited by 10
The biology of lipoprotein(a): From genetics to molecular mechanisms
Atallah, Nasrallah, N., Harb, T., Gerstenblith, G., & Leucker, T. M. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70133 · Cited by 9
Evolving strategies in cardiovascular disease prevention: 2025 American society for preventive cardiology highlights
Filtz, A., Shapiro, M. D., Whelton, P. K., Návar, A. M., Rodríguez, F., Martin, S. S., Gulati, M., Blankstein, R., Ridker, P. M., Bhatt, D. L., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101357 · Cited by 9
Development and Validation of a Clinical Polygenic Risk Report in U.S.-Based Health Systems for 8 Cardiovascular Conditions
Misra, A., Jowell, A. R., Haidermota, S., Perez, E. F., Mahanta, L., O'Brien, K. J., Anna, N., Hao, L., Truong, B. M. T., Aragam, K. G., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.03.035 · Cited by 9
Self-citation
All we need to know about lipoprotein(a)
Bess, C., Mehta, A., & Joshi, P. H. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.05.007 · Cited by 9
Prevalence of Lipoprotein(a) Measurement and its Association with Arteriosclerosis in Asymptomatic Individuals in China
Yang, P., Tang, L., Guo, H., He, Y., Qin, Y., Yan, L., Li, Z., Guo, Y.-Z., & Wang, J. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65214 · Cited by 9
LPA Genotypes and Haplotypes Are Associated with Lipoprotein(a) Levels but Not Arterial Wall Properties in Stable Post-Coronary Event Patients with Very High Lipoprotein(a) Levels
Likozar, A. R., Blinc, A., Podkrajšek, K. T., & Šebeštjen, M. (2021) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd8120181 · Cited by 9
Elevated Lipoprotein(a) prevalence and association with family history of premature cardiovascular disease in general population with moderate cardiovascular risk and increased LDL cholesterol
Gulayin, P., Lozada, A., Schreier, L. E., Gutiérrez, L., Lopez, G. I., Poggio, R., Mores, N., Ponzo, J., Calandrelli, M., Lanas, F. T., et al. (2022) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2022.101100 · Cited by 9
Lipoprotein(a) is a Prevalent yet Vastly Underrecognized Risk Factor for Cardiovascular Disease
Rendler, J., Murphy, M., & Yeang, C. (2024) · ASEAN Journal of Psychiatry · doi:10.54615/2231-7805.397 · Cited by 8
Blood Lipids, Lipoproteins, and Apolipoproteins With Risk of Coronary Heart Disease: A Prospective Study Among Racially Diverse Populations
Deng, K., Pan, X., Voehler, M., Cai, Q., Cai, H., Shu, X., Gupta, D. K., Lipworth, L. P., Zheng, W., & Yu, D. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.034364 · Cited by 8
Early health technology assessment of gene silencing therapies for lowering lipoprotein(a) in the secondary prevention of coronary heart disease
Burvill, A., Watts, G. F., Norman, R., & Ademi, Z. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.08.012 · Cited by 8
The influence of lipoprotein(a) on aortic valve calcification in patients undergoing transcatheter aortic valve replacement
Bormann, J., Rudolph, F., Miller, M., Waezsada, S., Kirchner, J., Bleiziffer, S., Friedrichs, K. P., Rudolph, V., Rudolph, T. K., & Gerçek, M. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-024-02587-z · Cited by 8
Standardising lipid testing and reporting in the United Kingdom; a joint statement by HEART UK and The Association for Laboratory Medicine
Kenkre, J. S., Mazaheri, T., Neely, R. D. G., Soran, H., Datta, D. B. N., Penson, P. E., Downie, P., Yates, A. M., Hayden, K., Patel, M., et al. (2025) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/00045632251315303 · Cited by 8
Impact of evolocumab on plaque phenotypic changes in patients with acute coronary syndrome and elevated lipoprotein(a) levels: a HUYGENS secondary analysis
Giovanni, G. D., Fujino, M., Kataoka, Y., Butters, J., Hucko, T., Puri, R., Nissen, S. E., Nelson, A. J., Psaltis, P. J., & Nicholls, S. J. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf211 · Cited by 8
Ignorance is not bliss: the importance of lipoprotein(a) testing
O’Donoghue, M. L., & Monguillon, V. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf422 · Cited by 8
Lipoprotein(a) in clinical practice: Risk stratification and therapeutic strategies
Nasrallah, N., Atallah, Harb, T., Gerstenblith, G., & Leucker, T. M. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70127 · Cited by 8
Extreme lipoprotein(a) in clinical practice: A cross sectional study
Zafrir, B., Aker, A., & Saliba, W. (2023) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2023.200173 · Cited by 8
Cardiometabolic predictors of high-risk CCTA phenotype in a diverse patient population
Kuno, T., Arce, J., Fattouh, M., Sarkar, S., Skendelas, J., Daich, J., Schenone, A., Zhang, L.-L., Rodriguez, C. J., Virani, S., et al. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100578 · Cited by 7
Measuring lipoprotein(a) for cardiovascular disease prevention – in whom and when?
Thomas, P. E., Vedel‐Krogh, S., & Nordestgaard, B. G. (2023) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001104 · Cited by 8
Independent Relationship of Lipoprotein(a) and Carotid Atherosclerosis With Long‐Term Risk of Cardiovascular Disease
Qi, Y., Duan, Y., Deng, Q., Yang, N., Sun, J., Li, J., Hu, P., Liu, J., & Liu, J. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033488 · Cited by 8
Clinical and Genomic Prediction of Coronary Artery Disease Subtypes
Liou, L., García‐González, J., Wu, H. M., Wang, Z., Hoggart, C. J., Kontorovich, A., Kovacic, J. C., & O’Reilly, P. F. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.321846 · Cited by 8
Longitudinal Assessment of Lipoprotein(a) Levels in Perinatally HIV-Infected Children and Adolescents
van Genderen, J. G., den Hof, M. V., de Boer, C. G., Jansen, H., van Deventer, S. J. H., Tsimikas, S., Witztum, J. L., Kastelein, J. J. P., & Pajkrt, D. (2021) · Viruses · doi:10.3390/v13102067 · Cited by 8
Lipoprotein(a) in the diagnosis of cardiovascular risk. The values of lipoprotein (a) and apolipoprotein B in the adult population of Krasnoyarsk
Emelyanchik, V. S., Валерьевна, М. О., Khomchenkov, R. V., Moiseeva, A. M., Чернова, А. А., Emelyanchik, E. Y., Nikulina, S. Y., & Protopopov, A. V. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5499 · Cited by 8
Association of free-living diet composition with plasma lipoprotein(a) levels in healthy adults
Matveyenko, A., Seid, H., Kim, K., Matienzo, N., Ramakrishnan, R., Thomas, T., & Reyes‐Soffer, G. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01884-2 · Cited by 8
The current status of lipoprotein (a) measurement in clinical biochemistry laboratories in the UK: Results of a 2021 national survey
Ansari, S., Neely, R. D. G., Payne, J., & Cegla, J. (2023) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/00045632231210682 · Cited by 7
Race/ethnicity and socioeconomic status affect the assessment of lipoprotein(a) levels in clinical practice
Pavlyha, M., Li, Y., Crook, S., Anderson, B. R., & Reyes‐Soffer, G. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.07.003 · Cited by 7
Lipoprotein(a) and peripheral artery disease: contemporary evidence and therapeutic advances
Thanigaimani, S., Kumar, M., & Golledge, J. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000998 · Cited by 7
Major cardiovascular events in first-degree relatives of individuals with elevated plasma lipoprotein(a): a registry-based cohort study
Kindborg, G., Hogling, D. E., Häbel, H., Yan, J., Hallerbäck, T., Lindhe, Ö., Hagström, E., Andersson, D. P., Littmann, K., & Brinck, J. W. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf677 · Cited by 7
Association between lipoprotein(a) and cardiovascular events in patients with peripheral artery disease: the Mass General Brigham Lp(a) registry
McClintick, D. J., Biery, D. W., Berman, A. N., Besser, S. A., Shiyovich, A., Singh, A., Huck, D. M., Weber, B., Cardoso, R. N., Bonaca, M. P., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf475 · Cited by 7
Lipoprotein(a) in Cardiovascular Diseases and Emerging Therapeutic Strategies
Al‐Horani, R. A., Selico-Dunn, A. C., & Smith, E. L. S. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07810-1 · Cited by 9
Effect of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors on Lipoprotein(a) Levels: An Umbrella Review of Meta-analyses of Randomized Controlled Trials
Qiao, W., Feng, Y., Wen, Z., Dou, L., & Li, Y. (2026) · Drugs · doi:10.1007/s40265-025-02274-x · Cited by 8
Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial
Monguillon, V., Marston, N., Bohula, E. A., Park, J., Kuder, J., Murphy, S. A., Ferrari, G. M. D., Leiter, L. A., Nicolau, J. C., Ebenbichler, C. F., et al. (2026) · Circulation · doi:10.1161/circulationaha.126.080999 · Cited by 7
Relationship Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Lipoprotein (a) and Other Biomarkers
Rossi, F. A. M., Agudelo, J. S., Castro, N. I. Q., Mosquera, S. Z., Fajardo, M. C. M., López, E. D. M., Olarte, J. D. E., Medina, M. A. F., Simancas, E. Z., & Osuna, L. F. S. (2024) · Cureus · doi:10.7759/cureus.63019 · Cited by 7
Strategies for management of patients with elevated lipoprotein(a)
Ellberg, C. C., & Bhatia, H. S. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000950 · Cited by 7
C-reactive protein in people with high lipoprotein a: a partner in crime or an innocent bystander?
Orringer, C. E. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad080 · Cited by 7
Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening
Khan, T. G., Bragazzi Cunha, J., Raut, C., Burroughs, M., Vyas, H. S., Leix, K., Goonewardena, S. N., Smrcka, A. V., Speliotes, E. K., & Emmer, B. T. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119174 · Cited by 6
The interactions of Lipoprotein(a) with common cardiovascular risk factors in cardiovascular disease risk: evidence based on the UK Biobank
Ao, L., Noordam, R., Jukema, J. W., van Heemst, D., & van Dijk, K. W. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101008 · Cited by 7
Lipoprotein(a) at a “Tipping Point”: case to move to universal screening
Bhatia, H. S. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101274 · Cited by 5
AI-driven aging digital twins: A roadmap for clinical translation in precision geriatrics
Li, C., Zuo, K., Duan, R., Ouyang, X., Zhang, L. Y., Zeng, L., & Ge, L. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102931 · Cited by 6
Genetic Evidence Linking Lipoprotein(a) to Cardiovascular Disease and the Potential Role of Aspirin: A Mendelian Randomization Study
Tan, J., Xu, W., Hu, S., Wang, J., Wang, L., Zhu, J. J., & Yang, Y. J. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm39322 · Cited by 6
Lipoprotein(a): An Underappreciated Inherited Risk Factor for Atherosclerosis, Aortic Stenosis, and Abdominal Aortic Aneurysm
Koschinsky, M. L., Kalra, D. K., & Boffa, M. B. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-050124-025051 · Cited by 6
Association of Lp(a) with Cardiovascular Disease and All-cause Mortality in US Hispanics and Latinos
Danilov, A., Luciano, P. D., Yuan, Y.-W., Gomes, D. C. D. O., López, J. A. G., Kent, S. T., Booth, J., Slipczuk, L., Martinez, C., Kaplan, R., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.09.1605 · Cited by 7
The additive prognostic value of lipoprotein(a) for all-cause and cardiovascular mortality across the traditional cardiovascular risk continuum: analysis from NHANES III (1988–1994) with follow-up to 2019
Al-Jarshawi, M. H. A., Chew, N., Bonaca, M. P., Ray, K. K., & Mamas, M. A. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag037 · Cited by 6
2025 ESC/EAS Dyslipidemia Guidelines Focused Update: Intensifying Prevention, Risk Stratification, and Therapy
Pradhan, A. K., Thandi, P., Mahajan, K., Iellamo, F., Perrone-Filardi, P., & Perrone, M. A. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.02.059 · Cited by 6
South Asian ethnicity: What can we do to make this risk enhancer a risk equivalent?
Gupta, K., Rifai, M. A., Hussain, A., Minhas, A. M. K., Patel, J., Kalra, D. K., Samad, Z. Z., & Virani, S. S. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.10.001 · Cited by 6
Consenso sobre lipoproteína (a) de la Sociedad Española de Arteriosclerosis. Revisión bibliográfica y recomendaciones para la práctica clínica
Delgado‐Lista, J., Mostaza, J. M., Arrobas-Velilla, T., Blanco‐Vaca, F., Masana, L., Pedro‐Botet, J., Pérez‐Martínez, P., Civeira, F., Cuende, J. I., Gómez-Barrado, J. J., et al. (2024) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2024.03.002 · Cited by 6
Fibrinogen and plasma clot properties are associated with apolipoprotein B and apolipoprotein B-containing lipoproteins in Africans
Bruwer, D., de Lange, Z., Koschinsky, M. L., Boffa, M. B., & Pieters, M. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.08.004 · Cited by 7
Lipoprotein(a) distribution in hospitalised Asian patients with ischaemic heart disease
Loh, W. J., Teo, C. B., Simon, O., & Yeo, C. (2024) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/17539447241306936 · Cited by 6
Lipoprotein(a) and Atrial Fibrillation: Mechanistic Insights and Therapeutic Approaches
Zhang, Z., Peng, B., Nuranmubieke, A., Xu, Y., Liu, Y., Tu, T., Lin, Q., Wang, C., Liu, Q., & Xiao, Y. (2024) · International Journal of Medical Sciences · doi:10.7150/ijms.102301 · Cited by 6
Optimizing Long-term Cardiovascular Risk Stratification: Integrating Biomarkers into the Very High-Risk ASCVD Definition in Asian Patients
Cheng, J., Wang, H., Song, C., Qiao, Z., Bian, X., Yin, D., Feng, L., Zhu, C., Yang, M., Gao, G., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.100965 · Cited by 6
Clinical significance of elevated lipoprotein(a) in primary and secondary prevention: a multi-institutional study
Chen, D., Tsai, M., Hsieh, M., Chang, C.-Y., Chen, T., Chen, S., Chu, P., Hsieh, C., Hung, K., Wen, M., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf649 · Cited by 6
Lipoprotein (a) variability is associated with mean follow-up C-reactive protein in patients with coronary artery disease following percutaneous coronary intervention
Zhang, S., Hu, W., Li, Y., Yu, J., Sang, S., Alsalman, Z. M., & Xie, D.-Q. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i35.12909 · Cited by 6
Supporting evidence for lipoprotein(a) measurements in clinical practice
Matveyenko, A., Pavlyha, M., & Reyes‐Soffer, G. (2023) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2023.101746 · Cited by 6
Burden of lipoprotein(a) for patients with atherosclerotic cardiovascular disease: A retrospective analysis from the United States
Fonseca, A. F., Byrne, H., Laguna-Fernández, A., Itani, T., Studer, R. L., Heo, J., Dillon, A., Ferber, P. C., & Costa‐Scharplatz, M. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.5.519 · Cited by 6
Consideration and Application of Lipoprotein(a) in the Risk Assessment of Atherosclerotic Cardiovascular Disease Risk in Adults
Yuen, T., Mancini, G. B. J., Hegele, R. A., & Pearson, G. J. (2023) · CJC Open · doi:10.1016/j.cjco.2023.11.015 · Cited by 6
Increased residual cardiovascular risk in U.S. veterans with moderately-elevated baseline triglycerides and well-controlled LDL-C levels on statins
Leatherman, S. M., Ferguson, R. E., Hau, C., Harrington, K. M., Granowitz, C. B., Philip, S., Toth, P. P., Bhatt, D. L., & Boden, W. E. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.982815 · Cited by 6
Predictors of lipoprotein(a) variability in clinical practice and their impact on cardiovascular risk
Joo, H. J., Yun, S. G., Park, J. H., Hong, S. J., Yu, C. W., Shin, S. Y., & Kim, E. J. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02666-8 · Cited by 6
Lepodisiran: Effects on Lipoprotein(a) and Cardiovascular Outcomes in Adults with Elevated Lp(a)
Kattamuri, L. P. V., Sharma, K., & Mukherjee, D. (2025) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x390148250908045359 · Cited by 5
Longitudinal changes and borderline reclassification of Lipoprotein(a) compared with conventional lipids in over 230,000 adults
Sung, D.-E., Lee, M.-Y., Kwon, M., & Sung, K. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120524 · Cited by 5
Focused update 2025 delle linee guida ESC/EAS 2019 per il trattamento delle dislipidemie
Mach, F., Koskinas, K. C., van Lennep, J. E. R., Tokgözoğlu, L. S., Badimón, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., Backer, G. D., et al. (2025) · Giornale italiano di cardiologia · doi:10.1714/4586.45945 · Cited by 5
Evolving guidelines on lipoprotein(a)
Boffa, M. B., Koschinsky, M. L., & Hegele, R. A. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001016 · Cited by 5
Predictive Biomarkers for Asymptomatic Adults: Opportunities, Risks, and Guidance for General Practice
Wiedermann, C. J., Engl, A., Piccoliori, G., & von Strobele-Prainsack, D. H. (2026) · Diagnostics · doi:10.3390/diagnostics16020196 · Cited by 5
Seventeen years to change practice: will the 2025 ESC/EAS dyslipidaemia guidelines finally break the Sisyphean cycle?
Ray, K. K., & Kronenberg, F. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120636 · Cited by 5
Circulating Ketone Bodies and Incident Cardiovascular Outcomes and Mortality: Insights From the UK Biobank
Chevli, P. A., Mirzai, S., Kazibwe, R., Kingsley, J., Wood, A. C., Yeboah, J., Slipczuk, L. N., Mehta, A., Bhatia, H. S., Pandey, A., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.042582 · Cited by 5
Addressing the Lp(a) hypothesis: will lowering Lp(a) decrease the risk of cardiovascular events?
Koschinsky, M. L., & Boffa, M. B. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01278-8 · Cited by 5
Lowering of Lipoprotein(a) with Olpasiran
Amo-Tweneboah, C., & Kaur, G. (2026) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x428489260113103704 · Cited by 6
Lipoprotein (a) and the Occurrence of Lipid Disorders and Other Cardiovascular Risk Factors in Patients without Diagnosed Cardiovascular Disease
Ratajczak, J. M., Kubica, A., Pietrzykowski, Ł., Michalski, P., Kosobucka, A., Buczkowski, K., Krintus, M., Jankowski, P., & Kubica, J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164649 · Cited by 5
Lipoprotein(a) in interventional cardiology: identifying patients at highest risk of recurrent cardiovascular events through early recognition – a case based review
Renkens, M. P. L., Coerkamp, C. F., Witte, L. S., Sivanesan, S., Nurmohamed, N. S., Westerterp, M., Serruys, P. W. J. C., Onuma, Y., Grundeken, M. J., Kalkman, D. N., et al. (2024) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2024.2387678 · Cited by 5
Serum Lipoprotein(a) Levels and Their Association with Atherosclerotic Cardiovascular Disease in Japan
Fujii, E., Ako, J., Takahashi, Y., Toda, M., Iekushi, K., & Yamashita, S. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64953 · Cited by 5
Lipoproteins predicting coronary lesion complexity in premature coronary artery disease: a supervised machine learning approach
Marcinkowska, M., Kuchta, A., Grešner, P. M., Figatowski, T., Kasprzyk, P., Targoński, R., Sobiczewski, W., Jaguszewski, M., Fijałkowski, M., Gruchała, M., et al. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1470500 · Cited by 5
Lipoprotein (a) levels and clinical decision-making: data from a Mexican cohort at a tertiary medical institution
Cruz‐Bautista, I., Flores-Jurado, Y., Álvarez, G. R., Salas-Aldana, M., Elías-López, D., Hernández-Franco, R. F., Rosales-Uvera, S. G., Vargas‐Vázquez, A., Valdez-Echeverría, R. D., Velasco, S. L. D. V., et al. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02610-w · Cited by 5
Lp(a) as a Risk Factor for Peripheral Artery Disease: Context Is Everything
Koschinsky, M. L., & Boffa, M. B. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.125.322137 · Cited by 5
Lipid profile and the variables associated with control of selected lipid parameters in patients of a large multi-specialist hospital in Poland - the Jurasz Lipid Study (JLS).
Ziółkowski, M., Ratajczak, J. M., Obońska, K., Adamski, P., Banach, M., Chlebus, K., Grymuza, M., Grzelakowska, K., Jankowski, P., Konarski, J., et al. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02712-5 · Cited by 5
Risk Factors of Secondary Cardiovascular Events in a Multi-Ethnic Asian Population with Acute Myocardial Infarction: A Retrospective Cohort Study from Malaysia
Ismail, S. R., Mohammad, M. S. F., Butterworth, A. S., Chowdhury, R., Danesh, J., Angelantonio, E. D., Griffin, S. J., Pennells, L. A. M., Wood, A., Noh, M. F. M., et al. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10060250 · Cited by 5
Lipoprotein(a) as a risk factor for atherosclerotic cardiovascular disease in patients in non-metropolitan areas of Brandenburg, Germany
Hillmeister, P., Li, K., Dai, M., Sacirovic, M., Pagonas, N., Ritter, O., Bramlage, P., Persson, A. B., Buschmann, I. R., & Zemmrich, C. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1302152 · Cited by 5
Lipoprotein (a) measurement: potential for personalized cardiovascular disease management in a patient with acute myocardial infarction
Zimodro, J. M., Gąsecka, A., Arski, P., Schwarz, J., Banach, M., & Gouni‐Berthold, I. (2024) · Archives of Medical Science · doi:10.5114/aoms/188252 · Cited by 5
Association between lipoprotein (a) and risk of atherosclerotic cardiovascular disease events among maintenance hemodialysis patients in Beijing, China: a single-center, retrospective study
Liang, Q., Zhang, G., & Jiang, L. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03690-z · Cited by 5
Is Lipoprotein(a) Clinically Actionable with Today’s Evidence? The Answer is Yes
Ma, G. S., Chiou, T. T., & Wilkinson, M. J. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01937-z · Cited by 5
Lp(a) (Lipoprotein[a]), an Exemplar for Precision Medicine
Hopewell, J. C., Clarke, R., & Watkins, H. C. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315549 · Cited by 5
Genetics to the Rescue
Koschinsky, M. L., & Boffa, M. B. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.06.004 · Cited by 5
Lepodisiran, an siRNA targeting lipoprotein(a) for the potential future treatment of cardiovascular disease
Fernando, P. M. S., Hooper, A. J., & Burnett, J. R. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2352129 · Cited by 5
Lipoprotein(a) as an early marker of cardiovascular events in high-risk subjects: insights from the Moli-sani cohort study
Gianfagna, F., Poli, S., Costanzo, S., Castelnuovo, A. F. D., Panzera, T., Curtis, A. D., Magnacca, S., Persichillo, M., Santi, L. D., Cristofani, C., et al. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1571395 · Cited by 4
Trends in lipoprotein(a) testing and impact on clinical care: A contemporary systemwide analysis
Mangla, M., Bimal, T., Akhabue, E., Huang, X., Koschinsky, M. L., Vaidean, G. D., Donnelly, J., Ayyalu, T., Mintz, G. L., & Gianos, E. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101402 · Cited by 4
Lipoprotein(a), atherosclerotic plaque burden, and long-term cardiovascular outcomes in patients with coronary artery disease
de Mira, J. V. F., Vlieger, S., Mulder, M. T., van der Zee, L., Oemrawsingh, R. M., Cheng, J. M., van Lennep, J. E. R., Daemen, J., Mieghem, N. M. V., Geuns, R. J. M. V., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag138 · Cited by 4

Authors: Patel, A. P., Wang, M., Pirruccello, J. P., Ellinor, P. T., Ng, K., Kathiresan, S., & Khera, A. V.
Affiliations: Broad Institute (US)
IBM Research - Cambridge (United States) (US)
Corresponding author: Khera, Amit V.
ORCID: Patel, Aniruddh P.
Wang, Minxian
Pirruccello, James P.
Ellinor, Patrick T.
Ng, Kenney
Kathiresan, Sekar
Khera, Amit V.
Venue: Arteriosclerosis, Thrombosis, and Vascular Biology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2021-01
Volume: 41
Issue: 1
Pages: 465-474
ISSN: 1079-5642 (ISSN-L)
1524-4636
DOI: 10.1161/atvbaha.120.315291
PMC: PMC7769893
OpenAlex: W3097307979
Cited by: 567
References: 50
Citations by year: 2026: 135 · 2025: 147 · 2024: 110 · 2023: 89 · 2022: 60 · 2021: 25
FWCI: 39.95
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: other-oa
Locations: Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion, other-oa)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: American Heart Association (R01 HL128914, 18SFRN34110082)
Massachusetts General Hospital
Broad Institute
Fondation Leducq (K24HL105780, 18SFRN34110082, 1RO1HL092577, T32HL007208, 14CVD01, R01HL128914)
Medical Research Council (MC_PC_17228)
National Heart, Lung, and Blood Institute (1RO1HL092577, R01HL128914, K24HL105780, R01HL092577, T32HL007208)
National Human Genome Research Institute (K08HG010155, 18SFRN34110082)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: lipoprotein(a), atherosclerotic cardiovascular disease, incident cardiovascular events, racial differences, risk gradient, primary prevention, secondary prevention, middle-aged adults, UK Biobank
MeSH terms: Race Factors, Heart Disease Risk Factors, Adult, Aged, Female, United Kingdom, Humans, Male, Middle Aged, Primary Prevention, Prognosis, Time Factors, Biomarkers, Incidence, Lipoprotein(a), Biological Specimen Banks, Risk Assessment, Atherosclerosis, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks